144 related articles for article (PubMed ID: 30621630)
1. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Vogl UM; Andalibi H; Klaus A; Vormittag L; Schima W; Heinrich B; Kafka A; Winkler T; Öhler L
BMC Cancer; 2019 Jan; 19(1):28. PubMed ID: 30621630
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Chen J; Hua Q; Wang H; Zhang D; Zhao L; Yu D; Pi G; Zhang T; Lin Z
BMC Cancer; 2021 Jul; 21(1):853. PubMed ID: 34301232
[TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Portal A; Pernot S; Tougeron D; Arbaud C; Bidault AT; de la Fouchardière C; Hammel P; Lecomte T; Dréanic J; Coriat R; Bachet JB; Dubreuil O; Marthey L; Dahan L; Tchoundjeu B; Locher C; Lepère C; Bonnetain F; Taieb J
Br J Cancer; 2015 Sep; 113(7):989-95. PubMed ID: 26372701
[TBL] [Abstract][Full Text] [Related]
4. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Assenat E; de la Fouchardière C; Portales F; Ychou M; Debourdeau A; Desseigne F; Iltache S; Fiess C; Mollevi C; Mazard T
ESMO Open; 2021 Dec; 6(6):100318. PubMed ID: 34837745
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Delahoussaye AM; Abi Jaoude J; Green M; Fujimoto TN; Molkentine J; Garcia Garcia CJ; Gay JP; Feng N; Marszalek J; Fowlkes N; Taniguchi CM
BMC Cancer; 2022 Feb; 22(1):174. PubMed ID: 35172762
[TBL] [Abstract][Full Text] [Related]
6. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ; Moorcraft SY; Conroy T; Hohla F; Allen P; Taieb J; Hong TS; Shridhar R; Chau I; van Eijck CH; Koerkamp BG
Lancet Oncol; 2016 Jun; 17(6):801-810. PubMed ID: 27160474
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD
Ann Oncol; 2016 Apr; 27(4):648-53. PubMed ID: 26802153
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Blazer M; Wu C; Goldberg RM; Phillips G; Schmidt C; Muscarella P; Wuthrick E; Williams TM; Reardon J; Ellison EC; Bloomston M; Bekaii-Saab T
Ann Surg Oncol; 2015 Apr; 22(4):1153-9. PubMed ID: 25358667
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Ko AH; Murphy PB; Peyton JD; Shipley DL; Al-Hazzouri A; Rodriguez FA; Womack MS; Xiong HQ; Waterhouse DM; Tempero MA; Guo S; Lane CM; Earwood C; DeBusk LM; Bendell JC
Oncologist; 2017 Dec; 22(12):1427-e129. PubMed ID: 28935773
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
De La Fouchardière C; Malka D; Cropet C; Chabaud S; Raimbourg J; Botsen D; Launay S; Evesque L; Vienot A; Perrier H; Jary M; Rinaldi Y; Coutzac C; Bachet JB; Neuzillet C; Williet N; Desgrippes R; Grainville T; Aparicio T; Peytier A; Lecomte T; Roth GS; Thirot-Bidault A; Lachaux N; Bouché O; Ghiringhelli F
J Clin Oncol; 2024 Mar; 42(9):1055-1066. PubMed ID: 38232341
[TBL] [Abstract][Full Text] [Related]
11. Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study.
Chang C; Li X; Cao D
BMC Cancer; 2021 May; 21(1):545. PubMed ID: 33985455
[TBL] [Abstract][Full Text] [Related]
12. Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer.
Kokkali S; Tripodaki ES; Drizou M; Stefanou D; Magou E; Zylis D; Kapiris M; Nasi D; Georganta C; Ardavanis A
In Vivo; 2018; 32(3):653-657. PubMed ID: 29695574
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma.
Yoon H; Shin Y; Ryoo BY; Jeong H; Park I; Seo DW; Lee SS; Park DH; Song TJ; Oh D; Hwang DW; Lee JH; Song KB; Park Y; Kwak BJ; Hong SM; Park JH; Kim SC; Kim KP; Yoo C
Pancreatology; 2024 May; 24(3):424-430. PubMed ID: 38395676
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Toxicity of Palliative Chemotherapy in Elderly Patients With Advanced Pancreatic Cancer.
Jeong HT; Kim HG; Han J
Pancreas; 2024 Mar; 53(3):e268-e273. PubMed ID: 38300837
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
[TBL] [Abstract][Full Text] [Related]
16. Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.
Bullock A; Rowan CG; Oestreicher N; Yeganegi H; Chiorean EG
J Manag Care Spec Pharm; 2020 Jul; 26(7):872-878. PubMed ID: 32584677
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis.
Isacoff WH; Reber HA; Bedford R; Hoos W; Rahib L; Upfill-Brown A; Donahue T; Hines OJ
Target Oncol; 2018 Aug; 13(4):461-468. PubMed ID: 29882102
[TBL] [Abstract][Full Text] [Related]
18. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
[TBL] [Abstract][Full Text] [Related]
19. A real-world analysis of second-line treatment option, Gemcitabine plus Anlotinib and anti-PD1, in advanced pancreatic cancer.
Fan M; Ma Y; Deng G; Si H; Jia R; Wang Z; Dai G
Pancreatology; 2024 Mar; ():. PubMed ID: 38553260
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Sohal DPS; Duong M; Ahmad SA; Gandhi NS; Beg MS; Wang-Gillam A; Wade JL; Chiorean EG; Guthrie KA; Lowy AM; Philip PA; Hochster HS
JAMA Oncol; 2021 Mar; 7(3):421-427. PubMed ID: 33475684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
